gastroesophageal cancer
Natera Signatera MRD Test to Guide, Assess Treatment in Phase II Gastroesophageal Cancer Study
The Signatera ctDNA test will be used to evaluate the efficacy of AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) in the Phase II DECIPHER trial.
Castle Biosciences Builds Skin Cancer Assay Data, Eyes Future Expansion as Q1 Sales Jump 74 Percent
Premium
The company highlighted clinical research progress for its two skin cancer tests and said it hopes to expand in the gastrointestinal cancer space in coming years.
Culmination Bio, Cofactor Genomics Team up on Study to Advance Immunotherapy Response Test
Culmination will give Cofactor access to over 4.5 million biological samples to advance the firm's assay to predict immunotherapy response in 11 cancer types.
Personalis, Duke University, Olink Collaborate on Immunotherapy Markers in Gastric Cancer
They plan to study the genomic, transcriptomic, and proteomic responses of gastroesophageal tumors following treatment with Merck's Keytruda.
Gastric Cancer Cases Frequently Harbor Genetic Risk Variants, Suggesting Germline Testing
Using panel sequence data for more than 500 esophagogastric cancer cases, researchers found pathogenic or likely pathogenic variants in almost 20 percent of those with gastric cancers.